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ABSTRACT
Objective To develop and implement a
methodology for capturing complete
haematological malignancy pathway data and
use it to identify variations in specialist palliative
care (SPC) referrals.
Methods In our established UK population-
based patient cohort, 323 patients were
diagnosed with acute myeloid leukaemia, diffuse
large B-cell lymphoma or myeloma between May
2005 and April 2008, and died before April 2010.
A day-by-day calendar approach was devised to
collect pathway data, including SPC referrals, to
supplement routinely collected information on
clinical presentation, diagnosis, treatment,
response, and date and place of death.
Results 155 (47.9%) of the 323 patients had at
least one SPC referral. The likelihood of referral
increased with survival (OR 6.58, 95% CIs 3.32 to
13.03 for patients surviving ≥1 year compared to
≤1 month from diagnosis), and varied with
diagnosis (OR 1.96, CIs 1.15 to 3.35 for myeloma
compared to acute myeloid leukaemia).
Compared to patients dying in hospital, those
who died at home or in a hospice were also more
likely to have had an SPC referral (OR 3.07, CIs
1.59 to 5.93 and 4.74, CIs 1.51 to 14.81,
respectively). No associations were found for age
and sex.
Conclusions Our novel approach efficiently
captured pathway data and SPC referrals,
revealing evidence of greater integration between
haematology and SPC services than previously
reported. The likelihood of referral was much
higher among those dying outside hospital, and
variations in practice were observed by diagnosis,
emphasising the importance of examining
diseases individually.
INTRODUCTION
Patients with haematological malignancies
are reported to be less likely to receive
input from specialist palliative care (SPC)
or hospice services than those with other
cancers.1 2 These diseases are associated
with uncertainty about when SPC refer-
rals should be made3; and they have sig-
nificantly shorter intervals between
referral and death compared to other
cancers.4 5 Patients with haematological
malignancies are also more likely to die
in hospital6–8; a finding that is consistent
across the disease spectrum despite the
very diverse individual diagnostic sub-
types.9 Although an evidence base is
beginning to emerge about these differ-
ences, explanations are still largely based
on speculation and anecdote. In the UK,
the Department of Health acknowledges
the challenges associated with the deliv-
ery of end-of-life and palliative care in
patients with haematological cancers, and
in 2003, published guidance recommend-
ing further integration between clinical
haematology and SPC services.10
Haematological malignancies are
common, representing 1 in 10 of all
cancers in the developed world.11 12
They are complex diseases, ranging from
those that are acute in onset and often
associated with poor survival, such as
acute myeloid leukaemia (AML); to those
that often follow a pathway of care closer
to chronic disease than malignancy, such
as myeloma. Treatments vary markedly
and may include a ‘watch and wait’
approach to care (where the patient is
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actively monitored and only treated at the time of
disease progression, or when they become particularly
symptomatic), intensive or non-intensive chemother-
apy, radiotherapy, bone marrow transplantation or
antibody therapy. Many patients also receive support-
ive care (particularly blood products), which may be
delivered alone or in combination with other treat-
ments. Surgery is rarely a curative option in these dis-
eases, although it may be used, for example, to
stabilise fractures caused by bone disease in patients
with myeloma. Finally, multiple lines of chemotherapy
treatment may be given, particularly for the diseases
that follow a continuous remitting/relapsing course.
Treatment may be given with curative intent, life-
prolonging intent (for diseases, such as myeloma
which is generally considered incurable at diagnosis),
or for disease and symptom control. In this respect,
the definition of ‘palliative care’ and the ‘transition’
from an active, life prolonging to a palliative approach
to care – which is recognised as being complicated
generally13 14–is particularly complex in these dis-
eases. Additionally, the symptom burden associated
with haematological malignancies is considered com-
parable to that of other cancers, with physical symp-
toms including fatigue, fever, bleeding, drowsiness,
oral stomatitis and pain; and psychological symptoms
including adjustment disorder, mood disorder and
anxiety.15–20 These problems arise due to both the
disease processes and associated complications, as well
as the side-effects and toxicities of treatments.21 No
correlation has been reported between the presence of
symptoms and the likelihood of access to SPC services
as a consequence of these.19 22
There is little existing evidence about the factors
determining differences in end-of-life care in patients
with haematological cancers. This potentially inhibits
identification of changes that could be introduced to
ensure that patients receive the most appropriate and
timely care, in a place of their choosing. Built on the
pre-existing infrastructure of an established
population-based patient cohort, the current research
programme was instigated to address these issues. Our
overarching aim was to develop and implement a
methodology to capture detailed information about
the care pathways (providers/settings) and transitions
(curative/life-prolonging and palliative) of patients
with specific haematological malignancies, during the
period of time between diagnosis and death. The
current paper describes the methodology, presents an
overview of the dataset, and examines variations in
SPC referral by age, sex, diagnostic sub-type, time
from diagnosis to death, and place of death.
METHODS
This programme of work was conducted within the
existing framework of the Haematological Malignancy
Research Network (http://www.HMRN.org), an
on-going patient cohort covering a population of 3.6
million (>2000 newly diagnosed haematological
malignancies each year) that is broadly representative
of the UK as a whole.23 24 Established in 2004,
HMRN is a collaboration between a clinical haematol-
ogy network, researchers at the University of York and
the Haematological Malignancy Diagnostic Service
(http://www.HMDS.info), which diagnoses all haem-
atological malignancies in the area coding to the latest
WHO classification scheme (currently ICD-O-3).25
HMRN operates with Section 251 support under the
National Health Service (NHS) Act 2006, enabling
the Health and Social Care Information Centre
(HSCIC) to provide us with nationwide information
on deaths, subsequent cancer registrations, and
Hospital Episode Statistics (HES). Additionally, all
patients have full treatment, response and outcome
data abstracted from their medical records by trained
nurses operating to clinical trial standards.
Within HMRN, patients with haematological malig-
nancies are treated at 14 hospitals. For the current
study, we identified all patients newly diagnosed with
AML, diffuse large B-cell lymphoma (DLBCL) and
myeloma between 1 May 2005 and 30 April 2008,
who received their first treatment at one of two large
teaching hospitals, and were deceased by 30 April
2010 (reflecting a minimum of 2 years and maximum
of 5 years follow-up). Patients living in the catchment
area of these two hospitals may access SPC services in
the hospital (in-patient and out-patient) and/or the
community setting; and hospice care is also available.
For this project, HMRN’s routinely collected data
were supplemented by more detailed information
abstracted from hospital records and community SPC
records, using a day-by-day calendar approach span-
ning the entire time from diagnosis to death. This
included details of all specific hospital events (out-
patient appointments, in-patient episodes, medical
specialities managing care and clinical decisions); SPC
contacts (referrals to the hospital and/or community
teams, type and frequency of contact and input); and
details of death (preferred and actual place of care
and death). Figure 1 summarises the data collection
framework, with blue boxes indicating the routine
data collection which takes place for all HMRN
patients and green boxes showing the additional
pathway data collected for patients in this study.
Data were entered into a calendar and event-based
relational database, with each key event having the
capacity to store information on multiple sub-events.
This permitted information, such as in-patient epi-
sodes, to be recorded alongside the specialists provid-
ing care and other important sub-events including, for
example, clinical decisions (such as transitions in care
or resuscitation status). This enabled detailed patient-
specific pathways to be constructed and manipulated
to highlight specific events and activities of interest.
Analyses were conducted with SAS (V.9.3),26 and
logistic regression was used to compare differences
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between patients who received SPC and those who
did not.
RESULTS
Of the 323 patients who were diagnosed and died
during the study period, 107 (33.1%) had AML, 102
(31.6%) DLBCL and 114 (35.3%) had myeloma
(table 1). Overall, 155 (47.9%) had at least one SPC
referral, and there were no differences between those
that were referred and those that were not in terms of
age or sex. Significant differences in referral patterns
were evident, however, by disease sub-type; patients
with myeloma being almost twice as likely to have an
SPC referral (OR 1.96, CIs 1.15 to 3.35) as those
with AML. The likelihood of referral also increased
with longer survival; patients surviving 1 year and
above, for example, were over six times more likely to
be referred (OR 6.58, 95% CIs 3.32 to 13.03) than
those dying within a month of diagnosis. Being
referred to the SPC team was also significantly asso-
ciated with place of death, and those dying at home
were three times more likely to be referred to SPC ser-
vices (OR 3.07, CIs 1.59 to 5.93) and those dying in
a hospice almost five times more likely (OR 4.74, CIs
1.51 to 14.81) compared with those dying in hospital.
Figure 1 Summary of data
With respect to the type of SPC input, referral to
the community team was slightly more common than
Figure 1 Summary of data.
Table 1 Patient characteristics by SPC referral
Total
n (%)
No SPC referral
n (%)
SPC referral
n (%) OR (95% CI)
Total 323 (100) 168 (100) 155 (100)
Sex
Male 178 (55.1) 92 (54.8) 86 (55.5) 1
Female 145 (44.9) 76 (45.2) 69 (44.5) 0.97 (0.63 to 1.51)
Age, years
≤60 58 (18.0) 28 (16.7) 30 (19.3) 1
61–74 122 (37.8) 61 (36.3) 61 (39.4) 0.93 (0.50 to 1.74)
75+ 143 (44.2) 79 (47.0) 64 (41.3) 0.76 (0.41 to 1.34)
Diagnosis
AML 107 (33.1) 61 (36.3) 46 (29.7) 1
DLBCL 102 (31.6) 61 (36.3) 41 (26.4) 0.89 (0.51 to 1.55)
Myeloma 114 (35.3) 46 (27.4) 68 (43.9) 1.96 (1.15 to 3.35)
Time from diagnosis to death (months)
≤1 75 (23.2) 59 (35.1) 16 (10.3) 1
1–6 83 (25.7) 47 (28.0) 36 (23.2) 2.82 (1.40 to 5.70)
6–12 62 (19.2) 25 (14.9) 37 (23.9) 5.46 (2.58 to 11.56)
12+ 103 (31.9) 37 (22.0) 66 (42.6) 6.58 (3.32 to 13.03)
Place of death
Hospital 240 (74.3) 138 (82.1) 102 (65.8) 1
Home 49 (15.2) 15 (8.9) 34 (21.9) 3.07 (1.59 to 5.93)
Hospice 18 (5.6) 4 (2.4) 14 (9.0) 4.74 (1.51 to 14.81)
Nursing home 16 (4.9) 11 (6.6) 5 (3.2) 0.62 (0.21 to 1.83)
AML, acute myeloid leukaemia; DLBCL, diffuse large B-cell lymphoma; SPC, specialist palliative care.
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referral to the hospital team, although we found that
62 (19.2%) patients received support from both hos-
pital and community services (table 2). Different refer-
ral practices were observed by diagnostic sub-type;
patients with AML being more likely to be referred to
the community than the hospital SPC team (37.4%
and 19.6%, respectively). Myeloma patients were
somewhat more likely to be referred to hospital than
community services (46.5% compared with 41.2%,
respectively), although a large proportion of these
patients (28.1%) were referred to both services.
DISCUSSION
This is the first study to examine referral to SPC ser-
vices in patients with AML, DLBCL and myeloma.
Importantly, we found evidence of greater integration
between clinical haematology teams and SPC services
than expected, with almost half the patients having at
least one referral. Variations with diagnosis were,
however, observed, and patients with myeloma were
more likely to be referred than those with AML or
DLBCL. We found important variations in referral
practices by duration of time from diagnosis to death,
with the likelihood of referral increasing with longer
survival. SPC referral was clearly associated with place
of death, and those referred were less likely to die in
hospital. Evidence of different types of SPC referral
(to the hospital or community team) was also noted
by diagnostic sub-type.
Strengths/weaknesses of study
With more than 300 patients, our study is the largest
in the UK and one of the largest in the world to
examine SPC referrals specifically in patients with
haematological cancers. Covering a population of 3.6
million, our patient cohort (HMRN) is generalisable
to the UK, and provides a robust, well-established
infrastructure for research.23 24 A major strength of
HMRN is that all diagnoses are routinely coded to
ICD-O-3,25 meaning that we were able to examine
variations between specific sub-types of haemato-
logical cancers, which is of particular importance
given that these diseases can differ so markedly, with
some being particularly indolent and others aggres-
sive. This characteristic has an impact on the duration
of survival, which is recognised as being associated
with likelihood of SPC referral; longer survival equat-
ing to increased chance of referral.27–30 The differ-
ences identified between the diseases included in this
study demonstrate the importance of being able to
examine specific sub-types in this way.
A further strength of our study is the enormous
breadth and depth of data that were collected for each
individual patient in the cohort. The complete treat-
ment pathway from diagnosis to death was examined,
therefore, encompassing hospital and community SPC
input during this time. Data routinely collected on all
HMRN patients to clinical trial standards formed the
basis from which the treatment pathways were devel-
oped. These were supplemented by specific event-
based information collected from detailed searching
of numerous sources, including paper and compu-
terised medical records. As a result of this multifa-
ceted approach, we are extremely confident that the
vast majority of SPC referrals were identified.
Although our on-going study may have raised
awareness of the importance of integration between
clinical haematology and SPC services in the study
area, much of the data collection occurred retrospect-
ively, and it is unlikely that this will have unduly influ-
enced referral practices. The study was conducted in
two large teaching hospitals, and while it is probable
that there are some differences in practice in other
geographical locations, we expect that our results are
likely to be generally illustrative of other areas. One
weakness of the study is that the maximum duration
of the follow-up period was only 5 years. This means
that the SPC contacts for myeloma and relapsed
DLBCL may have been underestimated, although it is
unlikely to have biased the results for AML, which is
associated with particularly poor survival. Finally, as
our study focused on specific haematological malig-
nancies, we do not have comparators for other
cancers (or indeed other haematological cancers), so
cannot comment on relative differences between
disease types.
Comparison with other studies
A number of studies examining SPC referrals have
included patients with haematological malignan-
cies.1 22 27–36 We observed much greater integration
between clinical haematology and SPC services than
Table 2 Type of SPC referral by diagnosis
Type of SPC referral
Total
n (%) SPC referral n (%)
Hospital
n (%)
Community
n (%)
Hospital and
community (n%)
Total 323 (100) 155 (47.9) 100 (31.0) 117 (36.2) 62 (19.2)
AML 107 (100) 46 (43.0) 21 (19.6) 40 (37.4) 15 (14.0)
DLBCL 102 (100) 41 (40.2) 26 (25.5) 30 (29.4) 15 (14.7)
Myeloma 114 (100) 68 (59.6) 53 (46.5) 47 (41.2) 32 (28.1)
AML, acute myeloid leukaemia; DLBCL, diffuse large B-cell lymphoma; SPC, specialist palliative care.
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was identified in the majority of these studies in the
UK or elsewhere, and whether examining hospital or
community referrals. The exception to this was a
large Australian study.28 It is difficult, however, to dir-
ectly compare our findings with the results from exist-
ing studies, initially because of the use of widely
varying methods of data collection, including inter-
views and questionnaires, as well as examination of
medical records and database linkages, for example,
to healthcare billing data. These studies have also
examined involvement of SPC services in different set-
tings (hospital or community), or with respect to spe-
cific services (such as Hospice at Home or Palliative
Home Care), and some have also included only very
small numbers of patients with haematological malig-
nancies. Previously reported studies have not been
able to categorise diseases as precisely as we have
done and, instead, have defined ‘haematological dis-
eases’ as a single group (including all leukaemias,
lymphomas and myeloma), or have examined all types
of lymphoma together and/or all types of leukaemia.
More rarely, some specificity has been imposed by
focussing on particular disease types, such as acute
leukaemias. Finally, the situation is further compli-
cated by the varied service provision inherent within
and between countries, as well as different cultural
practices.
Our results concur with other studies with respect
to the association between longer survival and increas-
ing likelihood of SPC referral,27–30 and also the asso-
ciation between SPC referral and fewer hospital
deaths for haematology patients and cancer patients in
general.28 30 35 37
Meaning of study: explanations and implications for
clinicians and policy makers
The differences we observed by diagnostic subgroup
are comprehensible with respect to individual disease
characteristics. Myeloma patients were referred more
frequently to SPC services than patients with AML
and DLBCL. By contrast with some of the other
haematological malignancies, myeloma has many
potential complications at diagnosis and relapse,
including bone disease and fractures, severe and
complex pain and renal failure. These problems often
require support from a multidisciplinary team of clini-
cians with expertise in these areas. SPC practitioners
are widely recognised and acknowledged for their
skills in the management of complex issues such as
these, particularly within the context of dealing with
a new or relapsed cancer diagnosis, and many of the
SPC referrals we identified were undoubtedly made in
order to capitalise on these skills.38 39
The high proportion of SPC referrals to community
services in patients with AML may have occurred due
to the lack of treatment options (beyond non-intensive
chemotherapy and blood transfusions) available to
older people with these diseases. This may mean that
the terminal nature of the disease is recognised earlier
in the care pathway (indeed at diagnosis), allowing
community services to be put in place well in advance
of the patient’s deterioration. Further referrals across
diseases are likely to have been made for a number of
reasons, including: management of complex symp-
toms, such as the severe toxicity resulting from inten-
sive treatment of AML in younger patients, or
peripheral neuropathy, which is a common side effect
of the chemotherapy used to treat myeloma and also
lymphoma; provision of terminal care; and discus-
sions about preferred place of care and death.
As mentioned above, SPC referrals may occur more
often in patients who survive longer because there is
adequate time to recognise that curative/life-
prolonging treatment options are diminishing, and
there is less chance of prolonged survival. The transi-
tion in this context is likely to occur over a period of
time, rather than being associated with sudden deteri-
oration and death. Furthermore, we noted fluctuations
in SPC involvement over time, with services with-
drawing as particular issues resolve, and then
re-engaging later if new concerns arise. These multiple
and often overlapping episodes also provided evi-
dence of interservice referrals and activities between
hospital and community teams.
SPC referral is undoubtedly associated with a reduc-
tion in hospital deaths, and this has clear implications
for practitioners, who are often the gatekeepers of
these services, as well as policy makers who are able
to encourage referrals at a national level. What is
unclear, however, is whether SPC referrals instigate
discussions about preferred place of care and death,
and the possibility of home/hospice death, or whether
the patient has decided that their preferred place of
care and death is home/hospice, and the referral was
made to the service to facilitate this. Nonetheless,
home deaths are clearly more likely to occur in
patients with SPC referrals, and so, this information is
important when considering how best to achieve pre-
ferred place of death when a patient and their family
decides that this is not hospital.
Unanswered questions and future research
Haematological malignancies are complex, and our
population-based patient cohort is now generating evi-
dence which is facilitating a better understanding of
palliative and end-of-life care in these diseases. We
observed a high rate of SPC referrals, but this does not
mean that patients who were not referred had unmet
needs; it is possible that these patients did not have par-
ticularly complex problems that required involvement
from SPC services, and so, were managed solely by the
clinical haematology team in the hospital or by general
practitioners and district nurses in the primary care
setting. Conducting similar studies in different geo-
graphical areas would be useful to further assess varia-
tions in practice. Comparing our results with a cohort
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examining non-haematological cancers would also
promote understanding of the differences between dis-
eases. Further research addressing the reasons for SPC
referral and non-referral, and differences in the pre-
ferred and actual place of death in patients with haem-
atological malignancies is also relevant.
CONCLUSIONS
We have reported evidence of integration between
haematology and SPC services, with more referrals
among myeloma patients compared to those with
AML or DLBCL. We found compelling indications that
referral to SPC services was closely associated with
death at home, although whether this is a direct result
of SPC involvement cannot be determined. Increased
integration between clinical haematologists and pallia-
tive care specialists may improve end-of-life planning
for patients and, particularly, the facilitation of home
death when this is the preferred place, even if the
disease trajectory mitigates against this for many.
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